Abstract
The neurotoxin MPP+ potently inhibited the striatal binding of [3H]-tyramine, a putative marker for the vesicular transporter of dopamine, and provoked a massive in vivo release of striatal dopamine. Tetrabenazine, an established ligand for the vesicular catecholamine carrier, potently inhibited [3H]-tyramine binding, tyramine-provoked striatal efflux of dopamine and the fast component of MPP(+)-induced dopamine release. It is concluded that MPP+ in the striatum, besides interacting with additional intracellular targets, avidly binds at a vesicular site functionally involved with the outward transport of dopamine.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Carboni S., Melis F., Pani L., Hadjiconstantinou M., Rossetti Z. L. The non-competitive NMDA-receptor antagonist MK-801 prevents the massive release of glutamate and aspartate from rat striatum induced by 1-methyl-4-phenylpyridinium (MPP+). Neurosci Lett. 1990 Sep 4;117(1-2):129–133. doi: 10.1016/0304-3940(90)90131-r. [DOI] [PubMed] [Google Scholar]
- Daniels A. J., Reinhard J. F., Jr Energy-driven uptake of the neurotoxin 1-methyl-4-phenylpyridinium into chromaffin granules via the catecholamine transporter. J Biol Chem. 1988 Apr 15;263(11):5034–5036. [PubMed] [Google Scholar]
- Del Zompo M., Ruiu S., Maggio R., Piccardi M. P., Corsini G. U. [3H]1-methyl-4-phenyl-2,3-dihydropyridinium ion binding sites in mouse brain: pharmacological and biological characterization. J Neurochem. 1990 Jun;54(6):1905–1910. doi: 10.1111/j.1471-4159.1990.tb04889.x. [DOI] [PubMed] [Google Scholar]
- Fairbrother I. S., Arbuthnott G. W., Kelly J. S., Butcher S. P. In vivo mechanisms underlying dopamine release from rat nigrostriatal terminals: II. Studies using potassium and tyramine. J Neurochem. 1990 Jun;54(6):1844–1851. doi: 10.1111/j.1471-4159.1990.tb04881.x. [DOI] [PubMed] [Google Scholar]
- Henry J. P., Scherman D. Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. Biochem Pharmacol. 1989 Aug 1;38(15):2395–2404. doi: 10.1016/0006-2952(89)90082-8. [DOI] [PubMed] [Google Scholar]
- Javitch J. A., D'Amato R. J., Strittmatter S. M., Snyder S. H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci U S A. 1985 Apr;82(7):2173–2177. doi: 10.1073/pnas.82.7.2173. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Reinhard J. F., Jr, Diliberto E. J., Jr, Viveros O. H., Daniels A. J. Subcellular compartmentalization of 1-methyl-4-phenylpyridinium with catecholamines in adrenal medullary chromaffin vesicles may explain the lack of toxicity to adrenal chromaffin cells. Proc Natl Acad Sci U S A. 1987 Nov;84(22):8160–8164. doi: 10.1073/pnas.84.22.8160. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rollema H., Kuhr W. G., Kranenborg G., De Vries J., Van den Berg C. MPP+-induced efflux of dopamine and lactate from rat striatum have similar time courses as shown by in vivo brain dialysis. J Pharmacol Exp Ther. 1988 Jun;245(3):858–866. [PubMed] [Google Scholar]
- Vaccari A., Gessa G. [3H]tyramine binding: a comparison with neuronal [3H]dopamine uptake and [3H]mazindol binding processes. Neurochem Res. 1989 Oct;14(10):949–955. doi: 10.1007/BF00965928. [DOI] [PubMed] [Google Scholar]
- Vaccari A. High affinity binding of [3H]-tyramine in the central nervous system. Br J Pharmacol. 1986 Sep;89(1):15–25. doi: 10.1111/j.1476-5381.1986.tb11116.x. [DOI] [PMC free article] [PubMed] [Google Scholar]